Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Journal of Viral Hepatitis
|
May 13, 2020
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
Julia Dietz, Olga V Kalinina, Johannes Vermehren, et al.
The New England Journal of Medicine
|
April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Nezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The New England Journal of Medicine
|
December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Patrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Gastroenterology
|
October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
E Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
The New England Journal of Medicine
|
February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Gideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
The Lancet. Oncology
|
November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
Journal of Hepatology
|
April 16, 2023
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B
Florian van Bömmel, Kerstin Stein, Renate Heyne, et al.
The New England Journal of Medicine
|
June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Marc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
The Lancet. Gastroenterology & Hepatology
|
August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones, Pol F Boudes, Mark G Swain, et al.
JHEP Reports : Innovation in Hepatology
|
April 7, 2023
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients
Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Journal of Viral Hepatitis
|
May 13, 2020
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
Julia Dietz, Olga V Kalinina, Johannes Vermehren, et al.
The New England Journal of Medicine
|
April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Nezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
The New England Journal of Medicine
|
December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Patrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Gastroenterology
|
October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
E Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
The New England Journal of Medicine
|
February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Gideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
The Lancet. Oncology
|
November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
Journal of Hepatology
|
April 16, 2023
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B
Florian van Bömmel, Kerstin Stein, Renate Heyne, et al.
The New England Journal of Medicine
|
June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Marc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
The Lancet. Gastroenterology & Hepatology
|
August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones, Pol F Boudes, Mark G Swain, et al.
JHEP Reports : Innovation in Hepatology
|
April 7, 2023
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients
Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
Page
of 11